US 7,473,428 B2
	Recombinant porcine adenovirus vector
Michael A. Johnson, Thornbury (Australia); Jeffrey Hammond, Jan Juc (Australia); Richard J. McCoy, North Balwyn (Australia); and Michael G. Sheppard, Eltham (Australia)
Assigned to VectoGen Pty Ltd., New South Wales (Australia)
Filed on Mar. 22, 2006, as Appl. No. 11/387,026.
Application 11/387026 is a continuation of application No. 09/485512, granted, now 7,323,177, previously published as PCT/AU98/00648, filed on Aug. 14, 1998.
Claims priority of application No. PO8560 (AU), filed on Aug. 14, 1997.
Prior Publication US 2006/0263387 A1, Nov. 23, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/235 (2006.01); A61K 39/295 (2006.01)

U.S. Cl. 424—199.1  [424/233.1; 424/93.2]

58 Claims

1. A method of vaccination of pigs against disease comprising administering to said pigs a first recombinant porcine adenovirus (PAV) vector stably incorporating, and expressing a heterologous nucleotide sequence encoding at least one antigenic determinant of said disease against which vaccination is desired, wherein said heterologous nucleotide sequence is inserted into a non-essential region of a site selected from the group consisting of the E3 region and map units 97-99.5 of PAV-3 wherein said PAV3 vector further comprises a heterologous nucleotide sequence encoding PAV-4 fiber.